Try
Jazz Pharmaceuticals plc (Ireland)
JAZZUnited States
97 filed reports · 555 financial concepts · 2 earnings calls · 0 media appearances
Filed reports
97 reports · Jun 2016 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 115 operating metrics, 631 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Current · 8-KSEC EDGAR | 49 | 566 | Sep 2016 to Jun 2026 |
| Quarterly · 10-QSEC EDGAR | 31 | 6,029 | Jun 2016 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 10 | 6,229 | Dec 2016 to Dec 2025 |
| Annual · 10-K/ASEC EDGAR | 7 | 7 | Dec 2019 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 3, 2026 | 11 | Open |
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 3, 2026 | 409 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 5, 2026 | 4 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 5, 2026 | 238 | Open |
| FY2025 | 10-K/A | Dec 31, 2025 | Apr 24, 2026 | 1 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 24, 2026 | 6 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 24, 2026 | 1,086 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Nov 5, 2025 | 10 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 5, 2025 | 282 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 6, 2025 | 172 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Aug 5, 2025 | 10 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 7, 2025 | 169 | Open |
Financial data
555 concepts · 12,831 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial526 concepts · 11,129 facts · Dec 2014 to Jul 2026
- Cash and cash equivalents at carrying value58 · Dec 2014 to Jun 2026
- Net income loss58 · Dec 2014 to Jun 2026
- Revenue58 · Dec 2014 to Jun 2026
- Allocated share based compensation expense57 · Dec 2014 to Jun 2026
- Allocated share based compensation expense net of tax57 · Dec 2014 to Jun 2026
- Amortization of intangible assets57 · Dec 2014 to Jun 2026
- Comprehensive income net of tax57 · Dec 2014 to Jun 2026
- Cost of product sales (excluding amortization of acquired developed technologies)57 · Dec 2014 to Jun 2026
- Employee service share based compensation tax benefit from compensation expense57 · Dec 2014 to Jun 2026
- Income tax expense benefit57 · Dec 2014 to Jun 2026
- Incremental common shares attributable to share based payment arrangements57 · Dec 2014 to Jun 2026
- Interest income expense nonoperating net57 · Dec 2014 to Jun 2026
- Operating income loss57 · Dec 2014 to Jun 2026
- Selling general and administrative expense57 · Dec 2014 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value56 · Dec 2014 to Jun 2026
- Deferred income tax expense benefit56 · Dec 2014 to Jun 2026
- Depreciation56 · Dec 2014 to Jun 2026
- Income loss from equity method investments56 · Dec 2014 to Jun 2026
- Increase decrease in accounts payable56 · Dec 2014 to Jun 2026
- Increase decrease in accounts receivable56 · Dec 2014 to Jun 2026
- Increase decrease in accrued income taxes payable56 · Dec 2014 to Jun 2026
- Increase decrease in accrued liabilities56 · Dec 2014 to Jun 2026
- Increase decrease in inventories56 · Dec 2014 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets56 · Dec 2014 to Jun 2026
Product4 concepts · 799 facts · Dec 2014 to Jun 2026
- Revenue792 · Dec 2014 to Jun 2026
- Loss contingency claims settled number4 · Jun 2016 to Dec 2017
- Xyrem2 · Dec 2018
- Radiopharmaceutical Products1 · Sep 2016
Guidance11 concepts · 559 facts · Nov 2016 to Aug 2026
- Revenue Guidance97 · Nov 2016 to Aug 2026
- Gross Margin Guidance80 · Nov 2016 to Aug 2026
- EPS (Diluted) Guidance78 · Nov 2016 to Nov 2025
- Effective Tax Rate Guidance68 · Feb 2018 to Aug 2026
- Net Income Guidance64 · Nov 2016 to Nov 2025
- Gross Margin Guidance (Adjusted (non-GAAP))44 · Nov 2016 to Aug 2026
- EPS (Diluted) Guidance (Adjusted (non-GAAP))42 · Nov 2016 to Nov 2023
- Effective Tax Rate Guidance (Adjusted (non-GAAP))36 · Feb 2018 to Aug 2026
- Net Income Guidance (Adjusted (non-GAAP))36 · Nov 2016 to Nov 2023
- Revenue Guidance (Net product revenues)12 · Nov 2017 to Aug 2021
- Operating Margin Guidance2 · Jan 2023
Geography11 concepts · 305 facts · Dec 2014 to Jun 2026
- Revenue189 · Dec 2014 to Jun 2026
- Property, Plant & Equipment, Net44 · Dec 2015 to Dec 2018
- Current foreign tax expense benefit12 · Dec 2019 to Dec 2024
- Deferred foreign income tax expense benefit12 · Dec 2019 to Dec 2024
- Defined contribution plan cost recognized12 · Dec 2014 to Dec 2017
- Income loss from continuing operations before income taxes foreign12 · Dec 2019 to Dec 2024
- United States12 · Dec 2019 to Dec 2024
- French Tax Authorities6 · Dec 2015 to Dec 2017
- Defined contribution plan employer matching contribution percent4 · Dec 2016 to Dec 2017
- Change in estimates1 · Dec 2024
- Patent box incentive benefit1 · Dec 2024
KPI3 concepts · 39 facts · Dec 2020 to Jun 2026
- Subscribers33 · Dec 2020 to Jun 2026
- Net Subscriber Additions4 · Sep 2024 to Jun 2025
- Subscribers YoY Change2 · Jun 2026
Segments
1,104 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or servicesrt:ProductOrServiceAxis27 members · 693 facts
- Xyrem50 · Dec 2016 to Jun 2026
- Defitelio Defibrotide47 · Dec 2016 to Jun 2026
- Product And Services Royalties And Contract Revenue47 · Dec 2016 to Jun 2026
- Vyxeos47 · Dec 2016 to Jun 2026
- Other Products46 · Dec 2016 to Jun 2026
- Product And Services Product Sales Net Of Deductions36 · Dec 2018 to Jun 2026
- Zepzelca36 · Dec 2018 to Jun 2026
- Xywav34 · Dec 2018 to Jun 2026
- Epidiolex Epidyolex32 · Dec 2019 to Jun 2026
- Total Neuroscience32 · Dec 2018 to Dec 2025
- Erwinaze And Erwinase31 · Dec 2016 to Dec 2023
- Rylaze Enrylaze31 · Dec 2019 to Jun 2026
- Sativex30 · Dec 2019 to Dec 2025
- Sunosi30 · Dec 2017 to Dec 2024
- High Sodium AG Oxybate Product Royalty Revenue23 · Dec 2021 to Jun 2026
- Oncology22 · Dec 2018 to Jun 2026
- Total Oncology20 · Mar 2022 to Dec 2025
- Total Oxybate19 · Dec 2018 to Jun 2023
- Product And Services Product Sales17 · Dec 2016 to Jun 2020
- Other Royalty And Contract Revenues14 · Mar 2022 to Jun 2026
- Ziihera14 · Dec 2022 to Jun 2026
- Modeyso11 · Dec 2023 to Jun 2026
- Prialt9 · Dec 2016 to Dec 2018
- Epilepsy4 · Mar 2025 to Jun 2026
- Other Royalties And Contract Revenue4 · Dec 2022 to Dec 2025
- Sleep4 · Mar 2025 to Jun 2026
- Product And Services Other Royalties And Contract Revenue3 · Dec 2021 to Dec 2023
Statement geographicalsrt:StatementGeographicalAxis5 members · 191 facts
- US71 · Dec 2016 to Jun 2026
- Europe47 · Dec 2016 to Jun 2026
- Other Countries47 · Dec 2016 to Jun 2026
- GB24 · Dec 2019 to Dec 2024
- IT2 · Dec 2024
Statement geographicalus-gaap:StatementGeographicalAxis11 members · 114 facts
- US20 · Dec 2014 to Mar 2018
- Europe16 · Dec 2014 to Mar 2018
- Other Countries16 · Dec 2014 to Mar 2018
- Ie11 · Dec 2015 to Dec 2018
- It11 · Dec 2015 to Dec 2018
- Us11 · Dec 2015 to Dec 2018
- Other countries11 · Dec 2015 to Dec 2018
- GB6 · Dec 2014 to Dec 2017
- IE6 · Dec 2014 to Dec 2017
- FR3 · Dec 2015 to Dec 2017
- IT3 · Dec 2015 to Dec 2017
Product or serviceus-gaap:ProductOrServiceAxis10 members · 106 facts
- Xyrem19 · Dec 2014 to Mar 2018
- Defitelio Defibrotide16 · Dec 2014 to Mar 2018
- Erwinaze And Erwinase16 · Dec 2014 to Mar 2018
- Other Products16 · Dec 2014 to Mar 2018
- Prialt16 · Dec 2014 to Mar 2018
- Psychiatry9 · Dec 2014 to Dec 2016
- Vyxeos9 · Dec 2015 to Mar 2018
- Product And Services Product Sales2 · Mar 2017 to Mar 2018
- Product And Services Royalties And Contract Revenue2 · Mar 2017 to Mar 2018
- Radiopharmaceutical Products1 · Sep 2016
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary165 claims from 10 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary206 claims from 10 reports · Sep 2024 to Jun 2026
- Risk-factor changes25 claims from 1 reports · Dec 2025
- Risk factors96 risks from 2 annual reports · 2024 to 2025
Earnings calls
2 calls · May 2026 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 3, 2026
- FY2026 Q1May 5, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.